Navigation Links
/C O R R E C T I O N from Source -- Resverlogix Corp./
Date:5/1/2008

In TO339 transmitted at 1617e today, an error occurred in the first paragraph. The timing of the live teleconference should have read: "9:00 am

MDT" and not "9:00 pm MDT". Corrected copy follows:

Resverlogix Notice of Conference Call & Webcast

TSX Exchange Symbol: RVX

CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on May 8, 2008 at 9:00 am MDT to provide a year-end update on both the science and the business aspects of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link: http://services.choruscall.com/links/resverlogix0800508.html or on Resverlogix's website at: http://www.resverlogix.com.
Participants can also dial in for the conference call:

Dial information is as follows:

International Dial In: 1 604 638 5340

North America Toll Free: 1 800 319 4610

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ETEX Announces Supply Agreement with AlloSource
2. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
3. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
4. United BioSource Acquires Leading Publication Planning Software and Services Company
5. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
6. Nova Biosource Fuels Expands Senior Executive Team
7. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
8. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
9. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
10. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
11. Honey bee invaders exploit the genetic resources of their predecessors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... SHELTON, Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE ... that its CEO, Eugene Seymour , MD, MPH, will present ... 5:30PM at the Waldorf-Astoria Hotel in New York City ... presentation will be in the Windsor Room at 5:30PM EST. Registered ... New York City . --> ...
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the premier ... to assist the medical and life science researchers that ... Virus infection.   CDC website . ... Zika virus is a single-stranded RNA virus of ... West Nile, Dengue and Chikungunya Viruses. Zika virus is ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
Breaking Biology News(10 mins):